3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Endocrine
2
NET
1
Conditions
Neuroendocrine Tumors
15
Paraganglioma
4
Meningioma
4
Carcinoma, Neuroendocrine
4
Pheochromocytoma
3
Gastro-enteropancreatic neuroendocrine tumor
2
Carcinoma, Medullary
2
Carcinoid Tumor
2
Somatostatinoma
1
Serotonin Syndrome
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Hypertension
1
Disease Progression
1
Carcinoma, Merkel Cell
1
Carcinoid Heart Disease
1
Breast Neoplasms
1
Advanced Lung Neuroendocrine Tumor
1
Adenoma, Islet Cell
1
Interventions
lanreotide
3
cabozantinib
3
Nivolumab
3
Everolimus
3
pasireotide
2
lutetium Lu 177 dotatate
2
ganitumab
2
Sunitinib
2
Octreotide
2
Erlotinib Hydrochloride
2
Bevacizumab
2
zimberelimab
1
telotristat ethyl
1
recombinant interferon alpha 2b-like protein
1
pertuzumab
1
pembrolizumab
1
nintedanib
1
ibrutinib
1
fosbretabulin
1
epothilone B
1
conatumumab
1
cixutumumab
1
carfilzomib
1
azaspirane
1
aflibercept
1
Temozolomide
1
Somatostatin
1
Random Allocation
1
Ramucirumab
1
Panitumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoid Tumor
×
lutetium Lu 177 dotatate
×
Clear all
NCT02754297
2024-08-21
P-PRRT
CHU de Quebec-Universite Laval
Phase 2
Active not recruiting
275 enrolled
NCT04039516
2020-08-04
CHARRT
King's College Hospital NHS Trust
Phase 2
Unknown
20 enrolled